---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-209064"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:17:23.835884+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spero reports Q2 loss $11.9M; FDA SPA for tebipenem HBr P3 trial

## Summary
- Net loss $11.9M ($0.23/sh) vs $28.7M ($0.87) in Q2 2022; revenue $2.7M.
- FDA SPA agreement on design of Phase 3 PIVOT-PO trial for tebipenem HBr; first patient expected Q4 2023.
- Sath Shukla appointed President and CEO effective Aug 1; succeeds Ankit Mahadevia (now Chairman).
- Cash $77.7M + $30M GSK milestone; cash runway into H2 2025.
- SPR720 Phase 2 trial enrolling, topline data H2 2024; SPR206 IND planned Q4 2023.

## SEC filing metadata
- accession: 0001193125-23-209064
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312523209064/0001193125-23-209064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312523209064/d494367d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-209064
- JSON: https://secwatch.observer/filing/0001193125-23-209064.json
- Plain text: https://secwatch.observer/filing/0001193125-23-209064.txt

## Key facts
- Earnings Releases
  Spero Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $2.7 million, net income net loss of $11.9 million, EPS $0.23 per basic and diluted share.
  - Period: second quarter ended June 30, 2023
  - Revenue: $2.7 million
  - Net income: net loss of $11.9 million
  - EPS: $0.23 per basic and diluted share
  - Result: reported results
  source text: Spero reported a net loss for the second quarter ended June 30, 2023 of $11.9 million or $0.23 per basic and diluted share of common stock, compared to a net loss of $28.7 million or $0.87 per basic and diluted share of common stock reported for the same period in 2022. Total revenues for the second quarter of 2023 were $2.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312523209064/0001193125-23-209064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.